⌘+K

Equity Story

Near term

6-12 MONTHS

We believe the two primary factors in Carasent’s equity story in 2026 are organic growth and scaling up adj. EBITDAC margins. On the organic growth side, we believe Carasent has ample opportunities in continuing to onboard new customers, as well as upselling to existing users. Furthermore, we believe the launch of the surgical module for Webdoc will drive new customer inflows. With regard to adj. EBITDAC, we believe Carasent will be able to keep its operating expenditure and capitalised development costs relatively flat Y/Y, which coupled with a gross margin of ~85%, results in our view of favourable operating leverage and should enable the company to raise margins, we believe.

Long term

6+ YEARS

We believe Carasent should be able to post solid growth over the longer term thanks to its competitive products and still relatively low penetration of ~13% in Sweden (its largest market). Furthermore, after the acquisition of Data-Al in Germany and the upcoming launch of Webdoc X there, Carasent has increased its growth runway markedly by adding ~SEK8bn of addressable market. Moreover, we believe continued efforts to expand the use-case of current products (such as the surgical module and Medsum) could contribute to long-term growth for the company. With a net cash position, we believe Carasent is well-positioned for capital allocation going forward.

Key risks

  • Failure to comply with regulatory requirements could impede the company’s ability to market its products.

  • Healthcare data is highly sensitive, and a cyber-attack could be damaging for Carasent.

  • Carasent primarily targets private healthcare clinics, meaning any political reforms limiting or prohibiting private healthcare would affect the company.

Fair value range

Price

Fair range high value

Fair range low value

Upper end: Organic growth accelerates on the back of VGR, Germany, and Stockholm, leading to higher growth and margins than we anticipate. Lower end: Margin uptake is more sluggish than anticipated due to higher-than-expected opex growth.

Valuation and methodology

We use a medium-term approach in our valuation methodology, where we discount 2028e sales (end of financial target period) back to today. The low end of our fair value range is derived by applying an EV/sales of 4.5x, ~30% below the 10-year average NTM EV/sales multiple of Nordic software peers, whereas at the top end of our fair value range we apply an EV/sales of 6x, the three-year NTM average of its peer group, and discount that back to today using a WACC of 10%.

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB